FENC vs SUPN vs ACAD vs PRGO vs PTCT

For growth investors, Fennec Pharmaceuticals Inc.

(FENC) is the stronger pick with 123. 7% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). PTC Therapeutics, Inc. (PTCT) offers the better valuation at 9. 5x trailing P/E, making it the more compelling value choice. Analysts rate Fennec Pharmaceuticals Inc. (FENC) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, PTC Therapeutics, Inc.

(PTCT) is the cheapest at 9. 5x versus ACADIA Pharmaceuticals Inc. at 9. 8x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, PTC Therapeutics, Inc.

(PTCT) delivered a total return of +89. 4%, compared to -60. 3% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: PTCT returned +852. 1% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Supernus Pharmaceuticals, Inc.

(SUPN) is the lower-risk stock at 0. 80β versus Fennec Pharmaceuticals Inc. 's 1. 78β — meaning FENC is approximately 122% more volatile than SUPN relative to the S&P 500. On balance sheet safety, Supernus Pharmaceuticals, Inc. (SUPN) carries a lower debt/equity ratio of 4% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Fennec Pharmaceuticals Inc.

(FENC) is pulling ahead at 123. 7% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: PTC Therapeutics, Inc. grew EPS 264. 5% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PTCT leads at 35. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

PTC Therapeutics, Inc.

(PTCT) is the more profitable company, earning 39. 4% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 39. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus -5. 1% for SUPN. At the gross margin level — before operating expenses — PTCT leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 55. 6x for ACADIA Pharmaceuticals Inc. — 50. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.

In this comparison, PRGO (9.

8% yield) pays a dividend. FENC, SUPN, ACAD, PTCT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, PTC Therapeutics, Inc.

(PTCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03), +852. 1% 10Y return). Fennec Pharmaceuticals Inc. (FENC) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PTCT: +852. 1%, FENC: -42. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: FENC is a small-cap high-growth stock; SUPN is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; PRGO is a small-cap income-oriented stock; PTCT is a small-cap high-growth stock. PRGO pays a dividend while FENC, SUPN, ACAD, PTCT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.